Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets

Stock News03-02

Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational drug GLR2037 tablets. The application acceptance numbers are CXHL2600098 and CXHL2600099, with notice numbers 2026LP00526 and 2026LP00527. GLR2037 tablets are a Class 1 chemical new drug, an androgen receptor protein degradation targeting chimera (ARPROTAC), independently developed by Gan & Lee Pharmaceuticals. and intended for the treatment of advanced prostate cancer. Currently, no PROTAC products have been approved for marketing globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121012946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121012946","market":"nz","top_or_hot":-1,"title":"Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets","media":"Stock News","content":"<p>Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational drug GLR2037 tablets. The application acceptance numbers are CXHL2600098 and CXHL2600099, with notice numbers 2026LP00526 and 2026LP00527. GLR2037 tablets are a Class 1 chemical new drug, an androgen receptor protein degradation targeting chimera (ARPROTAC), independently developed by Gan & Lee Pharmaceuticals. and intended for the treatment of advanced prostate cancer. Currently, no PROTAC products have been approved for marketing globally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-02 18:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational drug GLR2037 tablets. The application acceptance numbers are CXHL2600098 and CXHL2600099, with notice numbers 2026LP00526 and 2026LP00527. GLR2037 tablets are a Class 1 chemical new drug, an androgen receptor protein degradation targeting chimera (ARPROTAC), independently developed by Gan & Lee Pharmaceuticals. and intended for the treatment of advanced prostate cancer. Currently, no PROTAC products have been approved for marketing globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603087","symbol_name":"甘李药业","start_time":0,"source_url":"","article_id":"1121012946","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121012946","pubTimestamp":1772446337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"甘李药业获得GLR2037片剂临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":1},"content_text":"Gan & Lee Pharmaceuticals. (603087.SH) announced that the company has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its investigational drug GLR2037 tablets. The application acceptance numbers are CXHL2600098 and CXHL2600099, with notice numbers 2026LP00526 and 2026LP00527. GLR2037 tablets are a Class 1 chemical new drug, an androgen receptor protein degradation targeting chimera (ARPROTAC), independently developed by Gan & Lee Pharmaceuticals. and intended for the treatment of advanced prostate cancer. Currently, no PROTAC products have been approved for marketing globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121012946","isCrawlerRequest":true}